Abstract
Endothelial dysfunction, a well recognized marker of cardiovascular risk, is an early event in artheriosclerosis process. Diabetes mellitus, hypertension and dyslipidemia, known risk factors for coronary disease have been associated with endothelial dysfunction, which improves after the control of these factors. Statins have additional benefits on endothelial function not related to decreasing cholesterol levels, known as pleiotropic effects. Most recently it has been reported the effect of statins promoting bone marrow-derived mononuclear cells. These cells are positive for CD34 and KDR superficial markers of endothelial cellular lineage, which is consistent with the hypothesis that they constitute the endothelial progenitor cells. Circulating endothelial progenitor cells are involved in the repair process of the endothelium after endothelial-cell injury in myocardial ischemia, angina and other stressful situations. Recent studies have demonstrated an inverse relationship between the EPC count in peripheral blood and risk of developing a cardiovascular event. In addition, circulating EPC correlates with the presence of endothelial dysfunction and could play a role as a surrogate biologic marker in vascular function. The effect of statins on endothelial progenitor cells might contribute to improve endothelial function leading to a decrease in vascular risk, independently of their impact on LDL cholesterol. In this paper, we review the role of statins in EPC mobilization, its effect in endothelial function restoration and the relevance of this finding in cardiovascular risk. We also review future therapeutic implications.
Keywords: Statins, endothelial function, endothelial progenitor cells, nitric oxide, Akt pathway
Related Journals
Related eBooks
Related Articles
-
Diabetes Mellitus and Vascular Endothelial Dysfunction: Current Perspectives
Current Vascular Pharmacology Development of Sodium-Dependent Glucose Co-Transporter 2 Inhibitors as Potential Anti-Diabetic Therapeutics
Current Topics in Medicinal Chemistry MicroRNAs: Biomarkers for Cardiovascular Disease in Patients with Diabetes Mellitus
Current Topics in Medicinal Chemistry Regulation of Cardiac Nerves: A New Paradigm in The Management of Sudden Cardiac Death?
Current Medicinal Chemistry Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimers Disease
Current Neuropharmacology Metformin and Pregnancy Outcomes: Evidence Gaps and Unanswered Questions
Current Clinical Pharmacology The Complexity of Aging: Cancer Risk Among Elderly People and Infectious Risk Among Those with Cancer
Anti-Cancer Agents in Medicinal Chemistry Towards Standardized Stem Cell Therapy in Type 2 Diabetes Mellitus: A Systematic Review
Current Stem Cell Research & Therapy Novel Glitazones with Diverse Peroxisome Proliferator Activated Receptor Modulatory Potential
Current Bioactive Compounds Combination Therapies of DPP4 Inhibitors and GLP1 Analogues with Insulin in Type 2 Diabetic Patients: A Systematic Review
Current Vascular Pharmacology Psychosocial Factors and Diabetes Mellitus: Evidence-Based Treatment Guidelines
Current Diabetes Reviews Evidence of Lifestyle Modification in the Management of Hypercholesterolemia
Current Cardiology Reviews The Possible Hypoglycemic Mechanisms of Echinochrome
Current Diabetes Reviews Glucagon Like Peptide-1 and Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Anti-Diabetic Agents from Natural Products — An Update from 2004 to 2009
Current Topics in Medicinal Chemistry Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Diabetes Beyond Insulin: Review of New Drugs for Treatment of Diabetes Mellitus
Current Drug Discovery Technologies Gestational Diabetes Mellitus: Post-partum Risk and Follow Up
Reviews on Recent Clinical Trials Fighting Type-2 Diabetes: Present and Future Perspectives
Current Medicinal Chemistry IGF-1R Inhibitor Ameliorates Diabetic Nephropathy with Suppressed HMGN1/TLR4 Pathway
Endocrine, Metabolic & Immune Disorders - Drug Targets